| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/17/2005 | CA2532668A1 Emulsifying systems containing azetidine derivatives |
| 02/17/2005 | CA2532667A1 Semi-solid formulations for the oral administration of taxoids |
| 02/17/2005 | CA2532566A1 Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
| 02/17/2005 | CA2532452A1 Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors |
| 02/17/2005 | CA2532431A1 "7-substituted 3-nitro-pyrazolo [1,5-a] pyrimidines" |
| 02/17/2005 | CA2532351A1 Stable modifications of tegaserod hydrogen maleate |
| 02/17/2005 | CA2532344A1 Compositions comprising components coated with a liquid impermeable but gas permeable layer, use thereof for treating cutaneous and other exocrine gland diseases |
| 02/17/2005 | CA2531796A1 Aryl and heteroaryl compounds, compositions, and methods of use |
| 02/17/2005 | CA2531675A1 Combination of src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
| 02/17/2005 | CA2530037A1 Podophyllotoxin derivatives |
| 02/17/2005 | CA2529792A1 Hydrolytically-resistant boron-containing therapeutics and methods of use |
| 02/17/2005 | CA2529569A1 Isomaltulose or trehalose containing comestibles for sustained carbohydrate energy release and increased fat oxidation |
| 02/17/2005 | CA2529196A1 Benzodiazepine cgrp receptor antagonists |
| 02/17/2005 | CA2528904A1 Thiomorpholino steroid compounds, the use thereof for the preparation of meiosis-regulating medicaments and method for the preparation thereof |
| 02/17/2005 | CA2528879A1 Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superinfections and fungal recurrences |
| 02/17/2005 | CA2528510A1 Conserved hbv and hcv sequences useful for gene silencing |
| 02/17/2005 | CA2526900A1 Truncated fragments of alpha-synuclein in lewy body disease |
| 02/17/2005 | CA2526274A1 Prostate stem cell antigen (psca) variants and subsequences thereof |
| 02/17/2005 | CA2523676A1 Dna vaccine expressing ha1 of equine-2 influenza virus |
| 02/17/2005 | CA2501889A1 Use of beta-glucans against biological warfare weapons and pathogens including anthrax |
| 02/16/2005 | EP1507010A2 Control of the gene expression in eukaryotic cells |
| 02/16/2005 | EP1507005A2 Antisense modulation of BCL-X expression |
| 02/16/2005 | EP1506967A1 Dipeptidyl peptidase inhibitors |
| 02/16/2005 | EP1506962A2 Nitrogen-containing aromatic heterocycles |
| 02/16/2005 | EP1506960A1 Indole compounds as inhibitors of tubulin polymerisation for the treatment of angiogenesis-related disorders |
| 02/16/2005 | EP1506958A1 Process for producing shogaol and intermediates for the synthesis thereof |
| 02/16/2005 | EP1506955A1 Bicyclic amino acids as pharmaceuticals agents |
| 02/16/2005 | EP1506951A1 Preparation and application of transhintotalphenolic acid |
| 02/16/2005 | EP1506784A1 Identification of novel factors that block programmed cell death or apoptosis by targeting JNK |
| 02/16/2005 | EP1506781A1 Vaginal care composition |
| 02/16/2005 | EP1506780A2 Pharmaceutical formulations with macrolides alone or mixed with other active agents |
| 02/16/2005 | EP1506778A1 TGF-a EXPRESSION INHIBITORS |
| 02/16/2005 | EP1506777A1 Obesity preventive or ameliorator containing methylidene hydrazide compound as active ingredient |
| 02/16/2005 | EP1506776A1 Use of enzyme inhibitors of the dipeptidylpeptidase IV and/or of the aminopeptidase n , and pharmaceutical preparations thereof for the prevention or therapy of neurodegenerative diseases |
| 02/16/2005 | EP1506775A1 Use of sex steroid function modulators to treat wounds and fibrotic disorders |
| 02/16/2005 | EP1506774A1 Smooth muscle peristole inhibitor |
| 02/16/2005 | EP1506755A2 Patient temperature regulation apparatus |
| 02/16/2005 | EP1506285A2 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| 02/16/2005 | EP1506237A1 Treatment of cancer by the use of anti fas antibody |
| 02/16/2005 | EP1506214A1 6-11 bicyclic ketolide derivatives |
| 02/16/2005 | EP1506213A1 An antimicrobial agent |
| 02/16/2005 | EP1506212A2 Novel substituted sulfamate anticonvulsant derivatives |
| 02/16/2005 | EP1506211A1 C-aryl glucoside sglt2 inhibitors and method |
| 02/16/2005 | EP1506205A2 Novel azacyclic ethynyl derivatives |
| 02/16/2005 | EP1506204A2 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof |
| 02/16/2005 | EP1506202A1 1-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the prepartion thereof |
| 02/16/2005 | EP1506201A1 R-enantiomers of pyranoindole derivatives for treatment of hepatitis c |
| 02/16/2005 | EP1506200A2 Novel diazabicyclic biaryl derivatives |
| 02/16/2005 | EP1506198A1 5-ethylimidarotriazones |
| 02/16/2005 | EP1506197A1 Acyl bicyclic derivatives of pyrrol |
| 02/16/2005 | EP1506196A2 Pyrazolopyrimidines |
| 02/16/2005 | EP1506195A2 Non-nucleoside reverse transcriptase inhibitors |
| 02/16/2005 | EP1506193A1 Carbamate-substituted pyrazolopyridines |
| 02/16/2005 | EP1506192A1 Substituted pyrroline kinase inhibitors |
| 02/16/2005 | EP1506191A1 Benzoxazine and benzoxazinone substituted triazoles |
| 02/16/2005 | EP1506190A1 (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker |
| 02/16/2005 | EP1506189A1 Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| 02/16/2005 | EP1506188A1 Process for the preparation of a hydrate of an anthranilic acid derivative |
| 02/16/2005 | EP1506187A1 2-thio-substituted imidazole derivatives and their use in pharmaceutics |
| 02/16/2005 | EP1506186A1 Substituted heterocyclic compounds and methods of use |
| 02/16/2005 | EP1506185A1 Novel compounds and their use |
| 02/16/2005 | EP1506181A1 Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
| 02/16/2005 | EP1506180A1 Thiazolidine-4-one derivative, method for preparing the same, and pharmaceutical composition containing the same |
| 02/16/2005 | EP1506179A1 Benzoxazine derivatives as 5-ht6 modulators and uses thereof |
| 02/16/2005 | EP1506178A2 Bicyclic modulators of androgen receptor function |
| 02/16/2005 | EP1506176A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/16/2005 | EP1506174A2 Opioid and opioid-like compounds and uses thereof |
| 02/16/2005 | EP1506172A2 Hepatitis c virus inhibitors |
| 02/16/2005 | EP1506167A1 Hydroxy tetrahydro-naphthalenylurea derivatives |
| 02/16/2005 | EP1506166A1 Aminotetralin-derived urea modulators of vanilloid vr1 receptor |
| 02/16/2005 | EP1506162A2 Synthesis of benzonitriles and benzimidates |
| 02/16/2005 | EP1506041A1 Bisphosphonic acids for the treatment and prevention of osteoporosis |
| 02/16/2005 | EP1506040A2 Selective inos inhibitors for the treatment of respiratory diseases and conditions |
| 02/16/2005 | EP1506032A1 Aerosol drug inhibition of lung metastases |
| 02/16/2005 | EP1506030A1 Medicament respiratory delivery device and cartridge |
| 02/16/2005 | EP1506015A2 Pharmaceutical combination of pde5 inhibitors with ace inhibitors |
| 02/16/2005 | EP1506014A1 Process for the preparation and activation of substances and a means of producing same |
| 02/16/2005 | EP1506013A1 Chimeric allograft tolerance induction, monitoring and maintenance |
| 02/16/2005 | EP1506011A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 02/16/2005 | EP1506009A2 Glucan-based vaccines |
| 02/16/2005 | EP1506003A1 Soluble formulations comprising insulin aspart and insulin detemir |
| 02/16/2005 | EP1506000A1 Heterocyclicsulfonamide hepatitis c virus inhibitors |
| 02/16/2005 | EP1505997A1 Formulations useful in the treatment of male and female impotence |
| 02/16/2005 | EP1505996A1 Antifungal effects of morinda citrifolia |
| 02/16/2005 | EP1505994A1 Novel use of the extract of processed ginseng and saponin isolated therefrom |
| 02/16/2005 | EP1505991A1 A drugs association against influenza virus |
| 02/16/2005 | EP1505989A2 Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration |
| 02/16/2005 | EP1505988A1 Dual dispenser for aesthetically acceptable delivery of anhydrous skin treatment compositions |
| 02/16/2005 | EP1505987A2 Stable amorphous celecoxib composite and process therefor |
| 02/16/2005 | EP1505986A1 COMBINATION OF AN HMG-CoA REDUCTASE INHIBITOR AND A NITRATE ESTER |
| 02/16/2005 | EP1505984A2 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury |
| 02/16/2005 | EP1505983A2 Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
| 02/16/2005 | EP1505982A1 Trimegestone and estrogens for treating post menopausal disorders |
| 02/16/2005 | EP1505981A2 Utilization of inhibitors of egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph)/prostatic hypertrophy |
| 02/16/2005 | EP1505980A1 Microbicidal pyrimidine or triazine for preventing sexual hiv transmission |
| 02/16/2005 | EP1505979A1 Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles |
| 02/16/2005 | EP1505978A1 Polymorphic forms of phenyl oxazolidinone derivatives |
| 02/16/2005 | EP1505977A2 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes |
| 02/16/2005 | EP1505976A1 Synergistic combination of an opioid analgesic and a nsaid |
| 02/16/2005 | EP1505975A1 Compositions and method for treating infection in cattle and swine |